DexCom Inc (DXCM)vsNovocure Ltd (NVCR)
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
NVCR
Novocure Ltd
$15.51
+1.04%
HEALTHCARE · Cap: $2.09B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 611% more annual revenue ($4.97B vs $699.19M). DXCM leads profitability with a 20.1% profit margin vs -21.2%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
NVCR
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXCM.
Margin of Safety
+81.5%
Fair Value
$56.59
Current Price
$15.51
$41.08 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
15.6% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.9x book value
Weak financial health signals
ROE of -52.3% — below average capital efficiency
Earnings declined 6.0%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : NVCR
The strongest argument for NVCR centers on Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : NVCR
The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
DXCM profiles as a mature stock while NVCR is a growth play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
NVCR is growing revenue faster at 15.6% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 29/100), backed by strong 20.1% margins and 13.1% revenue growth. NVCR offers better value entry with a 81.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Novocure Ltd
HEALTHCARE · MEDICAL DEVICES · USA
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?